Summary & Overview
HCPCS J9213: Interferon alfa-2a Injection, 3 Million Units
HCPCS Level II code J9213 designates a 3 million unit injection of recombinant interferon alfa-2a. This code identifies the billed drug product and is used across outpatient infusion centers, oncology and infectious disease clinics, and physician offices where injectable biologic therapies are administered. Nationally, accurate use of J9213 matters for claims processing, clinical documentation, and tracking utilization of interferon-based therapies.
Key payers discussed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of clinical context for interferon alfa-2a injections, typical sites of service, and the role of the code in billing workflows. The publication also summarizes benchmarking and payer coverage themes, common modifier usage, and where to expect policy updates affecting billing and reimbursement.
This resource is intended to help billing managers, practice administrators, and health policy analysts understand the clinical identity of J9213, the payer landscape, and the types of operational and policy information relevant to managing claims for this injectable therapy.
Billing Code Overview
HCPCS Level II code J9213 represents an injection of interferon alfa-2a, recombinant, 3 million units. This medication is an injectable biologic agent used in the treatment of certain viral infections and malignancies where interferon alfa-2a is indicated.
Service type: Injectable medication administration
Typical site of service: Outpatient infusion/injection clinic or physician office
Data not available in the input for associated taxonomies, ICD-10 diagnoses, and related codes.
Clinical & Coding Specifications
Clinical Context
A 52-year-old patient with chronic hepatitis C infection presents to an outpatient infusion clinic for scheduled antiviral therapy. The clinician prescribes interferon alfa-2a, recombinant, 3 million units administered by subcutaneous injection on a thrice-weekly schedule as part of an interferon-based regimen. The clinical workflow includes verification of the medication order, patient consent and counseling about potential flu-like adverse effects, screening for contraindications (severe psychiatric disease, autoimmune disease, uncontrolled cardiac disease), baseline laboratory tests (CBC, liver function tests, thyroid function, and viral load), medication preparation by pharmacy, administration of the subcutaneous injection by a licensed nurse, observation for immediate reactions for 15–30 minutes, documentation of lot number and expiration, and scheduling follow-up labs and clinic visits to monitor response and toxicity. Billing for the drug is submitted using J9213 with appropriate service modifiers and diagnosis linkage to the patient’s hepatitis C or other qualifying diagnosis.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | No modifier present / standard claim | Use when no specific modifier applies to the service. |
22 | Increased procedural services | Rarely used for drug administration; used if additional work beyond usual injection administration is documented (e.g., extensive counseling or complex preparation).